vemurafenib + digoxin

This is a **combination** of two drugs: **vemurafenib**, a small molecule BRAF kinase inhibitor primarily used to treat BRAF V600E mutation-positive unresectable or metastatic melanoma, and **digoxin**, a cardiac glycoside used to treat heart failure and certain arrhythmias. The combination is not a marketed therapeutic product, but has been studied in pharmacokinetic drug-drug interaction trials. Vemurafenib is a potent inhibitor of P-glycoprotein (P-gp), which leads to significantly increased exposure (AUC and Cmax) of digoxin when coadministered. This combination is primarily relevant in the context of drug-drug interaction studies, with clinical guidance advising caution due to increased digoxin plasma concentrations and potential risk of digoxin toxicity[1][3][2][4][5].